可自乳化的多西他赛注射用组合物及其制备方法
By adding specific amounts of citric acid and phospholipids to docetaxel injection to form a self-emulsifying composition, the allergic reactions and chemical stability issues caused by Tween-80 are resolved, achieving good solubility and stability, simplifying the preparation process and improving medication safety.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- BEIJING DELIINJE PHARM TECH CO LTD
- Filing Date
- 2023-05-06
- Publication Date
- 2026-07-17
AI Technical Summary
Existing docetaxel injections contain Tween-80, which causes severe allergic reactions and chemical stability issues. Furthermore, new formulations that avoid Tween-80 introduce new toxic side effects or complex processes, making it difficult to achieve good solubility, self-emulsification ability, and stability.
A composition consisting of docetaxel, injectable oil, phospholipids, and a specific amount of citric acid is used to form a self-emulsifying injectable composition. When diluted with an aqueous carrier for injection, it exhibits good self-emulsifying ability and chemical stability, and the resulting emulsion has good physical stability.
It avoids allergic reactions caused by Tween-80, improves medication compliance, ensures the chemical stability of the composition and the physical stability of the diluted emulsion, simplifies the preparation process, and reduces preparation costs.
Smart Images
Figure BDA0004478686050000032 
Figure BDA0004478686050000061 
Figure BDA0004478686050000071